Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1969 of 6351
-
Spinal stimulation trial hopes to restore movement and bladder control
Symptom relief Recruiting nowNeurological disability caused by traumatic lesions of the spinal cord is a significant challenge for medicine and society. These lesions, leading to sublesional central nervous system dysfunction, include sensorimotor, vesico-sphincter and genito-sexual disorders. To date, there…
Sponsor: Hopital Foch • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New hope against deadly mold infections: generic drug shows promise
Disease control CompletedAmphotericin B Cholesteryl Sulfate Complex (ABCD) is a generic drug of amphotericin B colloidal dispersion. This study aimed to explore the safety and efficacy of ABCD in patients with invasive mold disease.
Phase 3 • Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Experimental brain tumor cocktail targets recurrent glioma
Disease control Recruiting nowThis is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
Phase 1 • Sponsor: Darell Bigner • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could an app replace the clinic for hand arthritis relief?
Symptom relief CompletedThe purpose of this study is to evaluate the effect of a 12 week digital treatment program for patients with hand osteoarthritis. The treatment consisted of exercises and educational sessions with respect to the disease, its natural course and recommended treatment strategies. D…
Sponsor: Joint Academy • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
New antibody shows promise for painful skin condition
Disease control CompletedEfficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa
Phase 2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New injection shows promise for controlling high blood pressure
Disease control CompletedThe purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
Phase 2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo aims to control lung cancer that returns after standard therapy
Disease control Recruiting nowThis phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after ch…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking some of the enzymes needed for c…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Blood test could spot lingering lung cancer after surgery
Knowledge-focused Recruiting nowctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Which blood thinner is safer? major trial pits rivaroxaban against apixaban
Disease control Recruiting nowAtrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others. Not only can it ruin one's life, but it can also be f…
Phase 4 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New gel pump for Parkinson's: Real-World results under scrutiny
Disease control OngoingThis observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia). Lecigon® is prescribed by physicians in advanced Parki…
Sponsor: Britannia Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Magnetic pulses to the brain could curb alcohol cravings
Disease control Recruiting nowThe purpose of this study is to develop transcranial magnetic stimulation (TMS), specifically TMS at a frequency known as theta burst stimulation (TBS), to see how it affects the brain and changes the brain's response to alcohol-related pictures. TMS and TBS are stimulation techn…
Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New radiation approach aims to stop pancreatic cancer return after surgery
Disease control OngoingWhile surgery is considered the only potentially curative therapy for pancreatic cancer, 5-year overall survival (OS) is typically \<25%. Following surgical resection of pancreatic cancer, adjuvant conventionally fractionated RT (CRT, delivering 45-54 Gy in 1.8-2.0 Gy per fractio…
Sponsor: Istituto Clinico Humanitas • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New pill shows promise for tough blood cancers in early trial
Disease control OngoingThe purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding coh…
Phase 1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gaming your way to recovery: can a sensor-guided tablet exercise prevent hospital deconditioning?
Prevention CompletedConventional in-hospital mobility programs are challenging to deliver to hospitalized infected patients (e.g., COVID-19) due to infection risk to staff, staffing shortages, and potential exposure of other patients. This study evaluates a tele-exergame mobility program, a self-adm…
Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Can a nightly eye drop tame severe nearsightedness in kids?
Disease control CompletedObjective: to evaluate the efficacy of different concentrations of atropine eye drops in controlling the progression (diopter, axial length) of high myopia in young children, and to compare the compliance, adverse reaction and regression rate of different concentrations of atropi…
Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Ancient herbs take on long COVID: a trial tests whether chinese medicine can soothe persistent fatigue
Symptom relief CompletedCOVID-19 has spread rapidly and now affects all over the world. On 11 March 2020, coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization (WHO). Most of the infected people will develop mild to moderate illness, for example fever, coug…
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Blood test may cut bleeding risk for heart patients on strong meds
Disease control OngoingThe objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).
Phase 4 • Sponsor: Fundación EPIC • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug combo aims to outsmart resistant ovarian cancer
Disease control Recruiting nowThis phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (re…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
Food as medicine: tailored meals show promise for diabetes and hunger
Disease control CompletedThe investigators propose a single-site, open-label, Phase II, community-based randomized clinical explanatory trial to test the efficacy of a medically tailored meal (MTM) interventions for adults with food insecurity and T2DM (Type 2 Diabetes Mellitus). While the efficacy of MT…
Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC